Clinical Trials and Novel Therapies TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT
Diseases
This Phase 1 study tests a new T cell therapy for children and adults with persistent viral infections after stem cell transplant or CAR T therapy.
Description
After a stem cell transplant or CAR T therapy, the immune system is weakened, making patients vulnerable to serious viral infections. Common viruses like Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus, and BK virus can become life-threatening if not controlled. This study uses multivirus-specific T cells (MVSTs), a type of white blood cells trained to fight viruses. These cells are collected from healthy donors, matched to the patient’s immune system (HLA match), and stored in a cell bank. When needed, they are thawed and given through an IV infusion. This trial builds on previous research showing that banked MVSTs can safely and effectively treat viral infections after transplant. The current study improves the production method to reduce side effects and expand access.
Eligibility
- Children and adults of any age
- History of stem cell transplant or CAR T therapy (must be at least 28 days post-transplant or CAR T therapy)
- Persistent or recurring infection with EBV, CMV, adenovirus, BK virus, or JC virus that does not respond (or patient cannot tolerate) standard antiviral treatments
- Must meet basic health criteria (e.g., hemoglobin ≥ 7.0 gm/dL)
Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov.
